Erythropoietin in aplastic anemia
β Scribed by Pavlovic-Kentera, V. ;Milenkovic, P. ;Ruvidic, R. ;Jovanovic, V. ;Biljanovic-Paunovic, L.
- Publisher
- Springer-Verlag
- Year
- 1979
- Weight
- 366 KB
- Volume
- 39
- Category
- Article
- ISSN
- 1432-0584
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Immunoreactive serum erythropoietin (EPO) was measured in anemic and non-anemic patients with acquired non-severe aplastic anemia (AA; n = 22) and myelodysplastic syndromes (MDS; n = 31) receiving or not androgens to examine the effect of androgen therapy and anemia on EPO levels in these disorders.
## Abstract Recombinant human granulocyte colonyβstimulating factor (rhGβCSF) and erythropoietin (rhEPO) were used to treat patients with aplastic anemia (AA). In terms of effects on erythrocyte recovery, the combined use of rhGβCSF and rhEPO showed a favorable response in 6 of 14 (42.9%) patients